DailyIQ
|
Sector:HealthcareAll sectors
Last updated 1 minute ago

COO·The Cooper Companies, Inc.

$.
-. (-.%)
After Hours
High
$62.73
Open
$62.59
Market Cap
12.19B
52W High
$89.83
Low
$61.98
P. Close
$62.03
P/E
30.37
52W Low
$58.89
Fwd P/E
12.40
Mean Target
-
Technical Score (1D)
18
SELL
News Sentiment
48
MIXED
Cooper Companies (COO) is facing headwinds from slower organic growth, particularly in its vision care segment, and ongoing concerns about its Asia-Pacific performance. This has contributed to the stock's significant underperformance relative to the broader market and its healthcare sector peers over the past year. While the stock has seen a recent uptick from its 52-week low, it remains down year-to-date, prompting analysts to review their target prices. Investors will be watching for any signs of improvement in organic growth, especially within the contact lens division, and developments in the Asia-Pacific region.
Earnings Summary
Cooper Companies, Inc. is a global medical device company with a dual focus on vision care and women's health. Its CooperVision division is a major provider of contact lenses for various vision needs, while the CooperSurgical segment offers fertility solutions and women's health devices. The company operates within the Healthcare sector, specifically the Medical Instruments & Supplies industry, marketing its diverse range of products and services to healthcare professionals and institutions worldwide. Cooper Companies has demonstrated consistent performance in its recent earnings reports. In Q4 2024, the company reported EPS of $0.92, slightly exceeding the estimate of $0.91, with revenue at $964.70 million. This positive trend continued into Q1 2025, where EPS was $0.96 against an estimate of $0.93, and revenue reached $1,002.30 million. For Q2 2025, EPS came in at $1.10, beating the $1.07 estimate, with revenue at $1,060.30 million. The most recent quarter, Q3 2025, saw EPS of $1.15, surpassing the $1.11 estimate, and revenue at $1,065.20 million. This pattern shows a consistent ability to meet or beat EPS estimates and achieve revenue growth. Historically, Cooper Companies has shown a steady year-over-year growth trajectory, underpinned by its strong presence in both the vision care and women's health markets. The company has a notable track record of beating analyst estimates for earnings per share, indicating reliable operational execution and effective market penetration. Revenue growth has also been a consistent feature, reflecting the demand for its diverse product portfolio and strategic market positioning. Recent news indicates a slight adjustment in analyst sentiment, with Argus Research lowering its price target for COO, suggesting a more cautious near-term outlook. Concurrently, the company announced the appointment of Paul Keel as an independent director to its Board, effective July 1, 2026. Keel's extensive CEO experience in the medical device sector is expected to enhance board oversight and strategic execution, signaling a focus on strengthening leadership and long-term value creation. Looking ahead, investors will be watching Cooper Companies' ability to sustain its earnings beats and revenue growth in the face of revised analyst expectations. Key will be the company's strategic execution and how the new board member's expertise influences operational improvements and future growth initiatives. Monitoring management's commentary on market dynamics and any further strategic updates will be important for assessing the company's path forward.

EPS

EstBeatMiss
$0.88$0.95$1.03$1.11$1.19Q4'24Q1'25Q2'25Q3'25Q1'26Q4'25
QtrEstActual+/−
Q4'25$1.03 - -
Q1'26$1.04$1.10+5.7%
Q3'25$1.11$1.15+3.3%
Q2'25$1.07$1.10+3.0%
Q1'25$0.93$0.96+3.3%
Q4'24$0.91$0.92+0.9%

Revenue

EstBeatMiss
$950M$982M$1.0B$1.0B$1.1BQ4'24Q1'25Q2'25Q3'25Q1'26Q4'25
QtrEstActual+/−
Q4'25$1.0B - -
Q1'26$1.0B$1.0B-1.2%
Q3'25 - $1.1B -
Q2'25 - $1.1B -
Q1'25 - $1.0B -
Q4'24 - $965M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

COO Stock Snapshot

COO is currently trading at $62.03, giving The Cooper Companies, Inc. a market cap of 12.19B and a P/E ratio of 30.4. Today's range spans $61.98–$62.73, with shares opening at $62.59 and moving up $0.00 (0.0%) from the prior close. DailyIQ's technical score sits at 18/100 (SELL) with a news sentiment reading of 48/100.

Over the past year COO has traded between $58.89 and $89.83 - the current price is +5.3% off the 52-week low and -30.9% from the high.

The bearish momentum on The Cooper Companies, Inc. (COO) - 18/100 (SELL), sentiment neutral at 48/100, price $62.03 (near 52-week lows) - is the type of setup where stop-loss selling from long-side momentum strategies amplifies the initial technical weakness. The current P/E ratio stands at 30.4. At 12.19B in Healthcare market cap, the 52-week range of $58.89–$89.83 provides the structural reference, and the lower end of that range becomes the next key test if the current SELL signal persists.

Analyst coverage for COO becomes a double-edged factor in a SELL phase: at 12.19B in Healthcare market cap, active coverage is high enough that downgrade risk is real and impactful. The 18/100 technical reading and neutral sentiment (48/100) at $62.03 (near 52-week lows) place the stock in the zone where one or two high-profile estimate cuts can convert a grinding decline into a sharper re-rating — the $58.89–$89.83 range establishes where that repricing lands.